Diagnosis

Council on Radionuclides and Radiopharmaceuticals, Inc. Supports the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2023

Retrieved on: 
Wednesday, March 1, 2023
Breast cancer, Prostate cancer, Breast, Medicare, Patient, Diagnosis, Council, Disease, Human services, MD, Society, CMS, Google Images, Society of Nuclear Medicine and Molecular Imaging, Nuclear medicine, Prostate, African Americans, OPPS, Health, Molecular imaging, Hospital, Physician, SNMMI, Medical imaging, Radiopharmaceutical

WASHINGTON, March 01, 2023 (GLOBE NEWSWIRE) -- The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R.

Key Points: 
  • WASHINGTON, March 01, 2023 (GLOBE NEWSWIRE) -- The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R.
  • 1199, the “Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2023” by Congressmen Neal Dunn (R-FL), Scott Peters (D-CA), Greg Murphy (R-NC), and Terri Sewell (D-AL).
  • The FIND Act will ensure that patients have access to precision diagnostic radiopharmaceutical (RP) drugs and promotes continued life-saving innovations in nuclear medicine.
  • Scientific advancements in diagnostic RP drugs are increasing precision in detecting disease and are informing better treatment options for patients.

Aptar Appoints Julie Xing to its Board of Directors

Retrieved on: 
Wednesday, March 1, 2023
Pharmaceutical, Other Manufacturing, Medical Supplies, Health, Packaging, Cosmetics, Manufacturing, Retail, AptarGroup, NYSE, Diagnosis, Woman, Corporation, Eli Lilly, Eli Lilly and Company, Thermo Fisher Scientific, Person, Digital health, Multiomics, Government, The Hong Kong University of Science and Technology, Multimedia, Marketing, History, Access, Greater China, Growth, ATR, Medtech, 3D printing, Management, Affymetrix, Biology, Mars

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Julie Xing has joined its Board of Directors.

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Julie Xing has joined its Board of Directors.
  • Since 2022, Julie has served as Executive Chair of the Board of Directors of Mundipharma China.
  • “We are pleased to welcome Julie Xing to our Board of Directors.
  • I am excited to join Aptar’s Board of Directors to build upon the Company’s more than 75-year history of developing innovative products that millions of people around the world use every day.”
    George Fotiades, Chairman of Aptar’s Board of Directors, stated, “We look forward to welcoming Julie to our highly talented, diverse and multi-cultural Board of Directors.

APA and AVMA Team Up to Encourage Americans to #Paws4MentalHealth

Retrieved on: 
Wednesday, March 1, 2023
Social media, Diagnosis, Veterinarian, Organization, Partnership, Veterinary medicine, Research, American Psychiatric Association, AVMA, APA, Environment, Pet, Human, American Veterinary Medical Association, Animal, Mental health, Health, Physician, Medicine

The American Psychiatric Association (APA) and American Veterinary Medical Association (AVMA), who collectively represent nearly 140,000 physicians and veterinarians, have entitled the effort #Paws4MentalHealth.

Key Points: 
  • The American Psychiatric Association (APA) and American Veterinary Medical Association (AVMA), who collectively represent nearly 140,000 physicians and veterinarians, have entitled the effort #Paws4MentalHealth.
  • “Veterinarians know first-hand the tremendously good impact pets can have on our lives and on our mental well-being,” said Lori Teller, D.V.M., AVMA president.
  • On March 29 at 1 p.m. Eastern, the APA and AVMA will host a Twitter chat about pets and mental health featuring leaders from both organizations under the hashtag #Paws4MentalHealth.
  • The APA is also the largest psychiatric association in the world with more than 38,000 physician members specializing in the diagnosis, treatment, prevention, and research of mental illnesses.

Antimicrobial Susceptibility Testing Market worth $4.7 billion | MarketsandMarkets

Retrieved on: 
Wednesday, March 1, 2023
Infection, Patient, Culture, Academic institution, Diagnosis, BD, Hospital, Antimicrobial, India, Investment, Growth, AST, Antibiotic, USD, Prevalence, Medical device, Pharmaceutical industry, Vaccine, Antibiotics, Retail

Based on the product type, the antimicrobial susceptibility testing market is segmented into Manual antimicrobial susceptibility testing products, Automated Laboratory Instruments, Culture and Growth Media, and Consumables.

Key Points: 
  • Based on the product type, the antimicrobial susceptibility testing market is segmented into Manual antimicrobial susceptibility testing products, Automated Laboratory Instruments, Culture and Growth Media, and Consumables.
  • North America accounted for the largest share of 35.4% of the antimicrobial susceptibility testing market in 2022.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=206359984
    Antimicrobial Susceptibility Testing Market Advantages:
    Antimicrobial susceptibility testing (AST) is a laboratory technique used to determine the susceptibility or resistance of microorganisms to antimicrobial drugs.
  • Here are some advantages of the antimicrobial susceptibility testing market:
    Accurate Diagnosis: Antimicrobial susceptibility testing provides accurate and reliable results for the diagnosis of bacterial infections.

Antimicrobial Susceptibility Testing Market worth $4.7 billion | MarketsandMarkets

Retrieved on: 
Wednesday, March 1, 2023
Infection, Patient, Culture, Academic institution, Diagnosis, BD, Hospital, Antimicrobial, India, Investment, Growth, AST, Antibiotic, USD, Prevalence, Medical device, Pharmaceutical industry, Vaccine, Antibiotics, Retail

Based on the product type, the antimicrobial susceptibility testing market is segmented into Manual antimicrobial susceptibility testing products, Automated Laboratory Instruments, Culture and Growth Media, and Consumables.

Key Points: 
  • Based on the product type, the antimicrobial susceptibility testing market is segmented into Manual antimicrobial susceptibility testing products, Automated Laboratory Instruments, Culture and Growth Media, and Consumables.
  • North America accounted for the largest share of 35.4% of the antimicrobial susceptibility testing market in 2022.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=206359984
    Antimicrobial Susceptibility Testing Market Advantages:
    Antimicrobial susceptibility testing (AST) is a laboratory technique used to determine the susceptibility or resistance of microorganisms to antimicrobial drugs.
  • Here are some advantages of the antimicrobial susceptibility testing market:
    Accurate Diagnosis: Antimicrobial susceptibility testing provides accurate and reliable results for the diagnosis of bacterial infections.

Mount Sinai Expert Urge Colon Cancer Awareness and Education to Reverse Decline in Screening Rates during Pandemic

Retrieved on: 
Wednesday, March 1, 2023
Colonoscopy, DNA, MD, CDC, Diagnosis, Colorectal cancer, Disease, Genetic counseling, Risk, Black, Inflammatory bowel disease, Rectum, Patient, Hereditary nonpolyposis colorectal cancer, CT, Mount Sinai Hospital (Manhattan), FIT, Diet, Child, FAP, Icahn School of Medicine at Mount Sinai, Common, Korea Disease Control and Prevention Agency, African Americans, Exercise, CDN, Ulcerative colitis, FOBT, Tobacco, Vegetable, Diarrhea, Endoscopy, MPH, Woman, IBD, Crohn's disease, Constipation, Obesity, Dietary supplement, Liquor, Large intestine, RD

NEW YORK, March 1, 2023 /PRNewswire-PRWeb/ -- Colorectal cancer is the second leading cause of cancer deaths in both men and women in the United States. Although highly treatable and preventable, about 140,000 Americans are diagnosed and more than 50,000 people die each year, according to the Centers for Disease Control and Prevention (CDC). The United States Preventative Task Force recommends starting age of screening from 45 to 50.

Key Points: 
  • NEW YORK, March 1, 2023 /PRNewswire-PRWeb/ -- Colorectal cancer is the second leading cause of cancer deaths in both men and women in the United States.
  • In an effort to increase awareness and screening, Mount Sinai has expanded Colorectal Cancer Awareness Initiatives across all eight hospital sites during the month of March to provide patients with access to health professionals to discuss prevention, screening options, and risk factors.
  • However, colorectal cancer disproportionately affects the Black community, where the rates are the highest of any racial/ethnic group in the US.
  • African Americans are 20% more likely to get colorectal cancer and about 40% more likely to die from colorectal cancer than most other groups.

Americans Note Overwhelming Positive Mental Health Impact of Their Pets in New Poll; Dogs and Cats Equally Beneficial

Retrieved on: 
Wednesday, March 1, 2023
Social media, Turtle, Family, Diagnosis, Dog, Anxiety, Bird, Ageing, Research, American Psychiatric Association, APA, Pet, Human, Animal, Cat, Mental health, Medicine, Nursing, Pet industry

Among the survey respondents, half (50%) said they had dogs, 35% said they had cats, and a third (31%) said they did not have any pets at home.

Key Points: 
  • Among the survey respondents, half (50%) said they had dogs, 35% said they had cats, and a third (31%) said they did not have any pets at home.
  • Among pet owners, a strong majority (86%) said their pets have a mostly positive impact on their mental health.
  • Dog owners (87%) and cat owners (86%) were equally likely to say so, while other pet owners (62%) were less likely.
  • When asked how much they worried about various stressors related to pets, pet owners were most worried about their pets aging or passing away (71%) and their pets’ health conditions (66%).

American Cancer Society Releases New Colorectal Cancer Statistics; Rapid Shifts to More Advanced Disease and Younger People

Retrieved on: 
Wednesday, March 1, 2023
Tissue, Alaska Natives, Colonoscopy, SEER, American Cancer Society Cancer Action Network, Surveillance, Cancer, Human, Diagnosis, Disease, Policy, ACS, Mortality, National Center for Health Statistics, North American Association of Central Cancer Registries, Colorectal cancer, Lymph, Health equity, National Cancer Institute, Research, Medical statistics, CMS, BBB National Programs, Meat, American Cancer Society, National Center for Complementary and Integrative Health, Medicare, CRC, Cost sharing, Large intestine, Centers for Medicare & Medicaid Services, Woman, Incidence, Dairy, Health insurance, Vaccine, Pharmaceutical industry, Epidemiology

ATLANTA, March 1, 2023 /PRNewswire/ -- Colorectal cancer is swiftly shifting to more advanced disease and younger individuals according to Colorectal Cancer Statistics 2023, a new report on cancer facts and trends by the American Cancer Society (ACS).

Key Points: 
  • ATLANTA, March 1, 2023 /PRNewswire/ -- Colorectal cancer is swiftly shifting to more advanced disease and younger individuals according to Colorectal Cancer Statistics 2023, a new report on cancer facts and trends by the American Cancer Society (ACS).
  • Overall, in 2023, an estimated 153,020 people will be diagnosed with CRC in the U.S., and 52,550 people will die from the disease.
  • These major findings are to be published today in CA: A Cancer Journal for Clinicians , alongside its consumer-friendly companion, Colorectal Cancer Facts & Figures 2023-2025, available on cancer.org .
  • "These highly concerning data illustrate the urgent need to invest in targeted cancer research studies dedicated to understanding and preventing early-onset colorectal cancer," said Dr. Karen E. Knudsen , CEO of the American Cancer Society.

New Clinical AI Solutions Enable Early Disease Detection and Proactive Care for Patients with Lower GI Disorders, Diabetes and Prediabetes

Retrieved on: 
Wednesday, March 1, 2023
Diabetes, EHR, Cancer, Quality of life, Diagnosis, Ad Lucem, Headache, Organization, Reveal, Partnership, Colorectal cancer, Risk, Workload, Patient, Conditional sentence, AI, Prediabetes, Medial, Cassidy, Stroke, Medical imaging, Pharmaceutical industry, Medical device

RALEIGH, N.C., March 1, 2023 /PRNewswire/ -- Lucem Health™ today announced the availability of its new early disease detection solutions, Lucem Health Reveal. Lucem Health Reveal leverages existing EHR data to identify patients who may be at a higher risk of serious or chronic disease. Reveal solutions surface previously undiscovered insights in readily available clinical data that can help provider organizations deliver greater clinical value for patients and more financial value to the organization.

Key Points: 
  • – Sean Cassidy, CEO, Lucem Health
    Sixty percent of Americans live with at least one serious or chronic disease, such as cancer, diabetes, stroke, or heart disease.
  • Reveal solutions leverage the promise of AI for early disease detection, and respect clinicians' limited capacity for added clicks, new workload, or administrative burden.
  • Reveal for Lower GI Disorders - Identifies patients who appear to be at higher risk for colorectal cancer and other serious lower GI disorders.
  • Reveal for Prediabetes Progression -Identifies patients who appear to be at higher risk of progressing from prediabetes to diabetes within 12 months.

New Clinical AI Solutions Enable Early Disease Detection and Proactive Care for Patients with Lower GI Disorders, Diabetes and Prediabetes

Retrieved on: 
Wednesday, March 1, 2023
Diabetes, EHR, Cancer, Quality of life, Diagnosis, Ad Lucem, Headache, Organization, Reveal, Partnership, Colorectal cancer, Risk, Workload, Patient, Conditional sentence, AI, Prediabetes, Medial, Cassidy, Stroke, Medical imaging, Pharmaceutical industry, Medical device

RALEIGH, N.C., March 1, 2023 /PRNewswire/ -- Lucem Health™ today announced the availability of its new early disease detection solutions, Lucem Health Reveal. Lucem Health Reveal leverages existing EHR data to identify patients who may be at a higher risk of serious or chronic disease. Reveal solutions surface previously undiscovered insights in readily available clinical data that can help provider organizations deliver greater clinical value for patients and more financial value to the organization.

Key Points: 
  • Reveal solutions surface previously undiscovered insights in readily available clinical data that can help provider organizations deliver greater clinical value for patients and more financial value to the organization.
  • Sixty percent of Americans live with at least one serious or chronic disease, such as cancer, diabetes, stroke, or heart disease.
  • Reveal solutions leverage the promise of AI for early disease detection, and respect clinicians' limited capacity for added clicks, new workload, or administrative burden.
  • Reveal for Lower GI Disorders - Identifies patients who appear to be at higher risk for colorectal cancer and other serious lower GI disorders.